A Phase 4 interventional study of Fluticasone propionate/salmeterol combination product and Salmeterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 39 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 6 that started in 2009, is one of 22 in phase 4, and was the 26th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 107 across the 43 interventional studies. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 43 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 69th largest by enrollment of the 236 interventional ones that give a count, is one of 19 that started in 2009, is one of 38 in phase 4, and was the 78th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.
Dyspnea, referred to by patients as "shortness of breath" or "breathlessness," is frequently associated with decreases in functional status, quality of life, and disabilities. Currently available questionnaires do not specifically address the shortness of breath component of COPD. The development of a patient reported outcome questionnaire that will specifically assess Shortness of Breath with Daily Activities (SOBDA) in patients with COPD is needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
Drug: Fluticasone propionate/salmeterol combination product
Salmeterol 50mcg DISKUS twice a day
Drug: Salmeterol
Placebo DISKUS twice a day
Drug: Placebo
Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
Salmeterol 50mcg DISKUS twice a day for 8 weeks
Placebo DISKUS twice a day for 8 weeks
Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value
Cronbach's alpha (CA) is a measure of the IC of the 13-item SOBDA questionnaire (completed via electronic diary by a sample of participants). It is the ratio of the variance (var.) of the sum of the individual scores and the var. of the total score. The var. of the sum of a group of independent variables is the sum of their var.; thus, if the variables are positively correlated, the var. of the sum will be increased. If the items making up the score are identical and so perfectly correlated, CA=1. If the items are independent, CA=0. Higher scores indicate a more reliable (precise) instrument.
Time frame: Day 1 of the 2-week Run-in Period
Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period
T-RR=stability during repeat measures over time in a stable population. SOBDA score was determined by the 13-item (it.) scoring algorithm, assigning a weekly mean score of 1-4 (higher scores=more severe breathlessness with daily activities) based on the mean of 7 days of data (or \>=4 days). Daily total score is computed from the mean of the participant's (par.) scores on the 13 it. (\>=7 it. must have non-missing responses). Only scores of stable par. (indicating no change \[score=3\] on the par.-completed Patient Global Assessment of Change \[PGAC\]; 1 \[ much worse\] to 5 \[much better\]) were used.
Time frame: Week 1 and Week 2 of the 2-week Run-in Period
Convergent Validity for the SOBDA Questionnaire Measured as Correlations of the Baseline SOBDA Score With Participant-completed Modified Medical Research Council (mMRC) and Physician-completed mMRC Scores at Visit 2
Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the participant/physician-completed mMRC Dyspnea Scale assessments. The physician/participant rated the degree of the participant's dyspnea (trouble breathing) on the 5-point mMRC scale (0, none; 4, very severe). Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other.
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2
Convergent validity is defined as the ability of the SOBDA questionnaire to measure the required information and was assessed by examining the relationship between the SOBDA score with the CGI-S score. Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe).
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2
Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the CRQ-SAS dyspnea domain score. Pearson's correlation coefficient is a measure of the linear dependence between 2 variables. A correlation of +1 or -1 will occur if the data from the 2 variables lie exactly on a line. The CRQ is a 20-item instrument measuring 4 domains (each measured on a scale of 1 \[maximum impairment\] to 7 \[no impairment\]) of functioning: mastery, fatigue, emotional function, and dyspnea.
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Physician-completed (PyC) mMRC Score at Visit 2
SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the PyC mMRC. The physician rated the degree of the participant's dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of PyC mMRC, both indicating increased levels of breathlessness.
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Participant-completed (ParC) mMRC Score at Visit 2
SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the ParC mMRC. The participant rated the degree of his/her dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of ParC mMRC, both indicating increased levels of breathlessness.
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Known Group Validity (KGV) for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of CGI-S Scores at Visit 2
SOBDA KGV refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the CGI-S score. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe). KGV was confirmed if the SOBDA score increased with increasing values of CGI-S, both indicating increased levels of breathlessness.
Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatement on Visit 2 (Day 1 of the 6-week Treatment Period)
Participants (Par.) Classified as Responders/Non-responders According to the Patient Global Assessment of Change (PGAC) Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/Premature Discontinuation (PD) (the End of the 6-week Treatment Period or PD)
The PGAC is par. completed on a 1-5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Responders were defined as par. with a rating of "better" or "much better" (score of 4 or 5) on the PGAC at the relevant week; non-responders were defined as par. with a response of "much worse," "worse," or "no change" on the PGAC. As pre-specified in the study protocol, results are presented independent of treatment allocation . The study objectives were to assess the measurement properties and validity of the SOBDA questionnaire independent of specific treatment effect.
Time frame: Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Change From the Previous Week to the Current Week's SOBDA Score by Participant-completed PGAC Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/PD (End of the 6-week Treatment Period or PD)
Responsiveness reflects the ability of the SOBDA questionnaire to detect change under conditions of known change. Responders (Rs)=participants (par.) with a rating of "better"/"much better" (score of 4/5) on the PGAC (range; 1 \[much worse\] to 5 \[much better\]) at the relevant week; NRs=par. with a response of "much worse," "worse," or "no change" (score of 3). Mean difference between Rs and NRs in the change from the previous week to the current week's SOBDA score was calculated. For Visit 3/PD, the change from Baseline to the last treatment week's SOBDA score for Rs and NRs was calculated.
Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Number of Participants Classified as Responders and Non-responders by Clinician Global Impression of Change Question (CGI-C) Response at Visit 3/PD
Clinicians were asked to provide their clinical impression regarding change in the participant's shortness of breath by CGI-C. This was evaluated on a 1-5 Likert scale: 1 (much worse) to 5 (much better), with 3 being no change. A CGI-C responder was defined as a participant who had a response of "better" (4) or "much better" (5), and a non-responder was defined as a participant who had a response of "much worse" (1), "worse" (2), or "no change" (3).
Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Number of Participants Classified as Responders and Non-responders by CRQ-SAS Dyspnea Domain Response at Visit 3/PD
A CRQ-SAS dyspnea domain responder was defined as a participant who had a score increase of 0.5 units or more for the dyspnea domain of the CRQ-SAS between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had a decrease in the score, or an increase of less than 0.5 units.
Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Number of Participants Classified as Responders and Non-responders by Physician-completed and Participant-completed mMRC Response at Visit 3/PD
A Physician-completed and Participant-completed mMRC responder was defined as a participant who had a score decrease of one unit or more between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had the same score or an increase in score.
Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Change From Baseline to Last Treatment Week in the SOBDA Score by CGI-C Responses at Visit 3/PD
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the CGI-C conducted at Visit 3/Premature Discontinuation were assessed.
Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Change From Baseline to Last Treatment Week in the SOBDA Score by CRQ-SAS Dyspnea Domain (DD) Responses at Visit 3/PD
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes of responders (Rs) versus non-responders (NRs). The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing). Changes in mean SOBDA scores during the last treatment week in Rs and NRs using definitions based on the CRQ-SAS DD conducted at Visit 3/PD were assessed.
Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Change From Baseline to Last Treatment Week in the SOBDA Score by Physician-completed mMRC and Participant-completed mMRC Responses at Visit 3/PD
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The mMRC ranges from 0 (no breathlessness except with strenous exercise) to 4 (too breathless to leave the house; breathless when dressing/undressing) and is completed by the clinician or the participant as indicated. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the Physician-completed (Ph-C) and Participant-completed (Pa-C) mMRC conducted at Visit 3/Premature Discontinuation were assessed.
Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
SOBDA Threshold for Response Assessed as Mean Change From the Previous Week's SOBDA Score Based on a Participant-completed PGAC Score Rated of "Better"
Changes from Baseline in the SOBDA score for responders (Rs) and non-responders (NRs) (using the PGAC assessment; 1 \[much worse\] to 5 \[much better\]), together with the cumulative proportions of Rs and NRs, was used to establish the threshold for defining SOBDA questionnaire Rs. The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on PGAC scores pre-specified as "better" or demonstrating meaningful improvement.
Time frame: Baseline (last week of the 2-week Run-in Period) and Weeks 1, 2, 3, 4, 5, and 6 (6-week Treatment Period)
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better"
The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on CGI-C scores pre-specified as "better" or demonstrating meaningful improvement. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse, 2, worse; 3, no change; 4, better; 5, much better.
Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better"
The threshold of response (TOR) is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit. The TOR was evaluated as the change from Baseline in the SOBDA score based on CRQ-SAS scores pre-specified as "better" or demonstrating meaningful improvement. The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing).
Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL
FEV1 response was rated as 1=No change or worse (i.e., change of \<50 mL); 2=Better (i.e., change of 50 to \<100 mL); 3=Much better (i.e., change of \>=100 mL). The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on study assessment (FEV1) scores pre-specified as "better" or demonstrating meaningful improvement.
Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
The number of participants "enrolled" in the Protocol reflects the number of participants starting treatment in the Double-blind Treatment Period.
| Milestone | Albuterol and/or Ipratropium: Run-in Period | Placebo: Double-blind Treatment Period | SAL 50 mcg: Double-blind Treatment Period | FSC 250/50 mcg: Double-blind Treatment Period |
|---|---|---|---|---|
| Started | 418 | 0 | 0 | 0 |
| Completed | 366 | 0 | 0 | 0 |
| Not completed | 52 | 0 | 0 | 0 |
| Withdrew: Adverse event | 8 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 | 0 |
| Withdrew: Study closed/terminated | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 10 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 0 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 14 | 0 | 0 | 0 |
| Milestone | Albuterol and/or Ipratropium: Run-in Period | Placebo: Double-blind Treatment Period | SAL 50 mcg: Double-blind Treatment Period | FSC 250/50 mcg: Double-blind Treatment Period |
|---|---|---|---|---|
| Started | 0 | 75 | 152 | 139 |
| Completed | 0 | 69 | 141 | 126 |
| Not completed | 0 | 6 | 11 | 13 |
| Withdrew: Adverse event | 0 | 3 | 3 | 7 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 4 |
| Withdrew: Study closed/terminated | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 7 | 1 |
Cronbach's alpha (CA) is a measure of the IC of the 13-item SOBDA questionnaire (completed via electronic diary by a sample of participants). It is the ratio of the variance (var.) of the sum of the individual scores and the var. of the total score. The var. of the sum of a group of independent variables is the sum of their var.; thus, if the variables are positively correlated, the var. of the sum will be increased. If the items making up the score are identical and so perfectly correlated, CA=1. If the items are independent, CA=0. Higher scores indicate a more reliable (precise) instrument.
| ratio of variance | All Participants: 2-week Run-in Period |
|---|---|
| Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value | 0.892 |
T-RR=stability during repeat measures over time in a stable population. SOBDA score was determined by the 13-item (it.) scoring algorithm, assigning a weekly mean score of 1-4 (higher scores=more severe breathlessness with daily activities) based on the mean of 7 days of data (or \>=4 days). Daily total score is computed from the mean of the participant's (par.) scores on the 13 it. (\>=7 it. must have non-missing responses). Only scores of stable par. (indicating no change \[score=3\] on the par.-completed Patient Global Assessment of Change \[PGAC\]; 1 \[ much worse\] to 5 \[much better\]) were used.
| scores on a scale | All Participants: 2-week Run-in Period |
|---|---|
| Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period | 0.01 ± 0.244 |
Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the participant/physician-completed mMRC Dyspnea Scale assessments. The physician/participant rated the degree of the participant's dyspnea (trouble breathing) on the 5-point mMRC scale (0, none; 4, very severe). Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other.
| Spearman rank correlation coefficient | All Participants: 2-week Run-in Period |
|---|---|
| Physician-completed mMRC, n=339 | 0.24 |
| Participant-completed mMRC, n=340 | 0.29 |
Convergent validity is defined as the ability of the SOBDA questionnaire to measure the required information and was assessed by examining the relationship between the SOBDA score with the CGI-S score. Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe).
| Spearman rank correlation coefficient | All Participants: 2-week Run-in Period |
|---|---|
| Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2 | 0.24 |
Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the CRQ-SAS dyspnea domain score. Pearson's correlation coefficient is a measure of the linear dependence between 2 variables. A correlation of +1 or -1 will occur if the data from the 2 variables lie exactly on a line. The CRQ is a 20-item instrument measuring 4 domains (each measured on a scale of 1 \[maximum impairment\] to 7 \[no impairment\]) of functioning: mastery, fatigue, emotional function, and dyspnea.
| Pearson's correlation coefficient | All Participants: 2-week Run-in Period |
|---|---|
| Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2 | -0.68 |
SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the PyC mMRC. The physician rated the degree of the participant's dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of PyC mMRC, both indicating increased levels of breathlessness.
| scores on a scale | All Participants: 2-week Run-in Period |
|---|---|
| PyC mMRC: 0 to 1, n=12 | 1.78 ± 0.196 |
| PyC mMRC: 2, n=200 | 2.08 ± 0.048 |
| PyC mMRC: 3, n=117 | 2.28 ± 0.063 |
| PyC mMRC: 4, n=10 | 2.73 ± 0.216 |
SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the ParC mMRC. The participant rated the degree of his/her dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of ParC mMRC, both indicating increased levels of breathlessness.
| scores on a scale | All Participants: 2-week Run-in Period |
|---|---|
| ParC mMRC: 0, n=12 | 1.92 ± 0.192 |
| ParC mMRC: 1, n=103 | 1.94 ± 0.066 |
| ParC mMRC: 2, n=138 | 2.20 ± 0.056 |
| ParC mMRC: 3, n=65 | 2.26 ± 0.083 |
| ParC mMRC: 4, n=22 | 2.73 ± 0.142 |
SOBDA KGV refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the CGI-S score. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe). KGV was confirmed if the SOBDA score increased with increasing values of CGI-S, both indicating increased levels of breathlessness.
| scores on a scale | All Participants: 2-week Run-in Period |
|---|---|
| CGI-S: 1, n=19 | 1.87 ± 0.156 |
| CGI-S: 2, n=236 | 2.11 ± 0.045 |
| CGI-S: 3, n=78 | 2.33 ± 0.080 |
| CGI-S: 4, n=5 | 2.72 ± 0.305 |
The PGAC is par. completed on a 1-5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Responders were defined as par. with a rating of "better" or "much better" (score of 4 or 5) on the PGAC at the relevant week; non-responders were defined as par. with a response of "much worse," "worse," or "no change" on the PGAC. As pre-specified in the study protocol, results are presented independent of treatment allocation . The study objectives were to assess the measurement properties and validity of the SOBDA questionnaire independent of specific treatment effect.
| participants | MITT Population: 6-Week Treatment Period |
|---|---|
| Responders, Day 8 (Baseline to Week 1), n=293 | 105 |
| Non-responders, Day 8 (Baseline to Week 1), n=293 | 188 |
| Responders, Day 15 (Week 1 to Week 2), n=303 | 91 |
| Non-responders, Day 15 (Week 1 to Week 2), n=303 | 212 |
| Responders, Day 22 (Week 2 to Week 3), n=299 | 83 |
| Non-responders, Day 22 (Week 2 to Week 3), n=299 | 216 |
| Responders, Day 29 (Week 3 to Week 4), n=285 | 62 |
| Non-responders, Day 29 (Week 3 to Week 4), n=285 | 223 |
| Responders, Day 36 (Week 4 to Week 5), n=277 | 77 |
| Non-responders, Day 36 (Week 4 to Week 5), n=277 | 200 |
| Responders, Day 43 (Week 5 to Week 6), n=119 | 31 |
| Non-responders, Day 43 (Week 5 to Week 6), n=119 | 88 |
| Responders, Last Treatment Week, n=151 | 45 |
| Non-responders, Visit 3/PD, n=151 | 106 |
Responsiveness reflects the ability of the SOBDA questionnaire to detect change under conditions of known change. Responders (Rs)=participants (par.) with a rating of "better"/"much better" (score of 4/5) on the PGAC (range; 1 \[much worse\] to 5 \[much better\]) at the relevant week; NRs=par. with a response of "much worse," "worse," or "no change" (score of 3). Mean difference between Rs and NRs in the change from the previous week to the current week's SOBDA score was calculated. For Visit 3/PD, the change from Baseline to the last treatment week's SOBDA score for Rs and NRs was calculated.
| scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| Baseline to Day 8, responders, n=105 | -0.26 ± 0.324 |
| Baseline to Day 8, non-responders, n=188 | -0.01 ± 0.254 |
| Day 8 to Day 15, responders, n=91 | -0.10 ± 0.280 |
| Day 8 to Day 15, non-responders, n=212 | 0.01 ± 0.222 |
| Day 15 to Day 22, responders, n=83 | -0.08 ± 0.223 |
| Day 15 to Day 22, non-responders, n=216 | 0.02 ± 0.183 |
| Day 22 to Day 29, responders, n=62 | -0.09 ± 0.198 |
| Day 22 to Day 29, non-responders, n=223 | 0.01 ± 0.193 |
| Day 29 to Day 36, responders, n=77 | -0.07 ± 0.245 |
| Day 29 to Day 36, non-responders, n=200 | 0.03 ± 0.169 |
| Day 36 to Day 43, responders, n=31 | -0.04 ± 0.167 |
| Day 36 to Day 43, non-responders, n=88 | 0.02 ± 0.240 |
| Baseline to Visit 3/PD, responders, n=45 | -0.21 ± 0.497 |
| Baseline to Visit 3/PD, non-responders, n=106 | -0.14 ± 0.423 |
Clinicians were asked to provide their clinical impression regarding change in the participant's shortness of breath by CGI-C. This was evaluated on a 1-5 Likert scale: 1 (much worse) to 5 (much better), with 3 being no change. A CGI-C responder was defined as a participant who had a response of "better" (4) or "much better" (5), and a non-responder was defined as a participant who had a response of "much worse" (1), "worse" (2), or "no change" (3).
| participants | MITT Population: 6-Week Treatment Period |
|---|---|
| Responders | 120 |
| Non-responders | 181 |
A CRQ-SAS dyspnea domain responder was defined as a participant who had a score increase of 0.5 units or more for the dyspnea domain of the CRQ-SAS between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had a decrease in the score, or an increase of less than 0.5 units.
| participants | MITT Population: 6-Week Treatment Period |
|---|---|
| Responders | 117 |
| Non-responders | 184 |
A Physician-completed and Participant-completed mMRC responder was defined as a participant who had a score decrease of one unit or more between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had the same score or an increase in score.
| participants | MITT Population: 6-Week Treatment Period |
|---|---|
| Physician-completed mMRC responders | 91 |
| Physician-completed mMRC non-responders | 210 |
| Participant-completed mMRC responders | 92 |
| Participant-completed mMRC non-responders | 209 |
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the CGI-C conducted at Visit 3/Premature Discontinuation were assessed.
| scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| Responders, n=120 | -0.25 ± 0.484 |
| Non-responders, n=181 | -0.03 ± 0.413 |
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes of responders (Rs) versus non-responders (NRs). The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing). Changes in mean SOBDA scores during the last treatment week in Rs and NRs using definitions based on the CRQ-SAS DD conducted at Visit 3/PD were assessed.
| Scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| Responders, n=117 | -0.32 ± 0.446 |
| Non-responders, n=184 | 0.01 ± 0.416 |
The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The mMRC ranges from 0 (no breathlessness except with strenous exercise) to 4 (too breathless to leave the house; breathless when dressing/undressing) and is completed by the clinician or the participant as indicated. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the Physician-completed (Ph-C) and Participant-completed (Pa-C) mMRC conducted at Visit 3/Premature Discontinuation were assessed.
| Scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| Ph-C mMRC, responders, n=91 | -0.13 ± 0.416 |
| Ph-C mMRC, non-responders, n=210 | -0.11 ± 0.472 |
| Pa-C mMRC, responders, n=92 | -0.18 ± 0.508 |
| Pa-C mMRC, non-responders, n=209 | -0.09 ± 0.428 |
Changes from Baseline in the SOBDA score for responders (Rs) and non-responders (NRs) (using the PGAC assessment; 1 \[much worse\] to 5 \[much better\]), together with the cumulative proportions of Rs and NRs, was used to establish the threshold for defining SOBDA questionnaire Rs. The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on PGAC scores pre-specified as "better" or demonstrating meaningful improvement.
| scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| Baseline to Week 1, n=97 | -0.26 ± 0.325 |
| Week 1 to Week 2, n=82 | -0.08 ± 0.219 |
| Week 2 to Week 3, n=70 | -0.08 ± 0.216 |
| Week 3 to Week 4, n=49 | -0.10 ± 0.216 |
| Week 4 to Week 5, n=66 | -0.08 ± 0.255 |
| Week 5 to Week 6, n=26 | -0.05 ± 0.181 |
The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on CGI-C scores pre-specified as "better" or demonstrating meaningful improvement. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse, 2, worse; 3, no change; 4, better; 5, much better.
| Scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better" | -0.25 ± 0.484 |
The threshold of response (TOR) is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit. The TOR was evaluated as the change from Baseline in the SOBDA score based on CRQ-SAS scores pre-specified as "better" or demonstrating meaningful improvement. The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing).
| Scores on a scale | MITT Population: 6-Week Treatment Period |
|---|---|
| SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better" | -0.13 ± 0.417 |
FEV1 response was rated as 1=No change or worse (i.e., change of \<50 mL); 2=Better (i.e., change of 50 to \<100 mL); 3=Much better (i.e., change of \>=100 mL). The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on study assessment (FEV1) scores pre-specified as "better" or demonstrating meaningful improvement.
| mL | MITT Population: 6-Week Treatment Period |
|---|---|
| SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL | -0.16 ± 0.492 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/75 (5.3%) | 14/75 (18.7%) |
| SAL 50 mcg | — | 5/151 (3.3%) | 34/151 (22.5%) |
| FSC 250/50 mcg | — | 3/139 (2.2%) | 37/139 (26.6%) |
| Event | Placebo | SAL 50 mcg | FSC 250/50 mcg |
|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 4/75 | 2/151 | 0/139 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/75 | 0/151 | 1/139 |
| Myocardial InfarctionCardiac disorders | 0/75 | 0/151 | 1/139 |
| Suicide AttemptPsychiatric disorders | 0/75 | 0/151 | 1/139 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/75 | 1/151 | 0/139 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/75 | 1/151 | 0/139 |
| Impaired Gastric EmptyingGastrointestinal disorders | 0/75 | 1/151 | 0/139 |
| Chest PainGeneral disorders | 0/75 | 1/151 | 0/139 |
| PneumoniaInfections and infestations | 0/75 | 1/151 | 0/139 |
| DehydrationMetabolism and nutrition disorders | 0/75 | 1/151 | 0/139 |
| Event | Placebo | SAL 50 mcg | FSC 250/50 mcg |
|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 4/75 | 3/151 | 0/139 |
| HeadacheNervous system disorders | 2/75 | 6/151 | 5/139 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/75 | 4/151 | 1/139 |
| Respiratory Tract InfectionInfections and infestations | 2/75 | 0/151 | 0/139 |
| CandidiasisInfections and infestations | 1/75 | 0/151 | 3/139 |
| Sinus HeadacheNervous system disorders | 0/75 | 0/151 | 3/139 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/75 | 3/151 | 2/139 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/75 | 3/151 | 0/139 |
| Chest PainGeneral disorders | 1/75 | 3/151 | 0/139 |
| Sinus CongestionRespiratory, thoracic and mediastinal disorders | 0/75 | 1/151 | 2/139 |
| Age, Continuous(Years) | Placebo | SAL 50 mcg | FSC 250/50 mcg | Albuterol and/or Ipratropium: Run-in Failure | Total |
|---|---|---|---|---|---|
| Mean | 62.8 ± 9.82 | 60.1 ± 9.58 | 60.2 ± 9.45 | 63.8 ± 9.61 | 61.1 ± 9.65 |
| Sex: Female, Male(Participants) | Placebo | SAL 50 mcg | FSC 250/50 mcg | Albuterol and/or Ipratropium: Run-in Failure | Total |
|---|---|---|---|---|---|
| Female | 29 | 63 | 60 | 27 | 179 |
| Male | 46 | 89 | 79 | 25 | 239 |
| Race/Ethnicity, Customized(participants) | Placebo | SAL 50 mcg | FSC 250/50 mcg | Albuterol and/or Ipratropium: Run-in Failure | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 9 | 12 | 12 | 8 | 41 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| White | 65 | 140 | 127 | 44 | 376 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Oct 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 8 months after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Salmeterol Xinafoate
Pulmonary Disease, Chronic Obstructive →